Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)

The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.

Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism.

AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent.

Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore the latest data on ALS treatment with SLS-005."

Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions.

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&P 500 also fell, dropping, 0.20% to 5,146.8.

The stock market is navigating a mixed closing session this week, with the S&P 500 and Nasdaq 100 struggling to stave off a weekly downturn.

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.